The telomerase reverse transcriptase is upregulated in the majority of human cancers and contributes directly to cell transformation. Here we report that hTERT is phosphorylated at threonine 249 during mitosis by the serine/threonine kinase CDK1. Clinicopathological analyses revealed that phosphorylation of hTERT at threonine 249 occurs more frequently in advanced cancers. Using CRISPR/Cas9 genome editing, we introduced substitution mutations at threonine 249 in the endogenous hTERT locus and found that phosphorylation of threonine 249 is necessary for hTERTmediated RNA dependent RNA polymerase (RdRP) activity but dispensable for reverse transcriptase activity. Cap Analysis of Gene Expression (CAGE) demonstrated that hTERT phosphorylation at 249 regulates the expression of specific genes that are necessary for cancer cell proliferation and tumor formation. These observations indicate that phosphorylation at threonine 249 regulates hTERT RdRP and contributes to cancer progression in a telomerase independent manner.
Introduction
Recent analyses of human cancer genomes revealed that somatic mutations within the promoter of human telomerase reverse transcriptase (hTERT) occur at high frequency in over 50 distinct cancer types (1-6). These common promoter mutations are associated with higher expression levels of hTERT and a poor prognosis (5, (7) (8) (9) . In humans, experiments involving live cell imaging techniques combined with CRISPR-Cas9 genome editing demonstrated that recruitment of hTERT and hTERC to telomeres occurs through dynamic interactions between telomerases and the chromosome end during S-phase (10) . Although these observations indicate that recruitment of telomerase holoenzyme to the telomere is regulated in cell-cycle dependent manner, only a small subset of hTERT forms interactions with telomeres and Cajal bodies even in S-phase (10) and the regulation and function of the majority of hTERT outside S-phase is poorly understood.
Results

Mitotic specific accumulation of hTERT
Since it has been challenging to detect endogenous hTERT (11, 12) , we extensively validated available hTERT-specific antibodies against hTERT including the mouse monoclonal antibody (mAb) (clone 10E9-2), the mouse mAb (clone 2E4-2), the sheep polyclonal Abs (pAbs) abx120550 and the rabbit mAb ab3202. Specifically, we performed validation experiments by (i) immunoprecipitation (IP) with anti-hTERT antibodies followed by immunoblotting (IB) ( Fig. 1A) ,
(ii) suppression of hTERT by siRNAs specific for hTERT (13, 14) followed by IP-IB ( Fig. S1A) and (iii) recovery of telomerase activity with these antibodies as gauged by direct telomerase assay (12, 15) (Fig. S1B) . In each case, we found that the 10E9-2, the 2E4-2, the abx120550 and the ab32020 identified hTERT ( Fig. 1A and Fig. S1 ), confirming the sensitivity and specificity of these antibodies.
We previously reported that hTERT protein localizes to mitotic spindles (16) and hTERT protein expression is enriched in mitosis (14) (Fig. 1A) . We reconfirmed the enrichment of hTERT protein in mitosis using the antibodies described above (12) (Fig. 1A , two right panels). In addition, we confirmed mitotic specific accumulation of hTERT at the mRNA level (Fig. S2) . These observations suggest that expression of hTERT protein is regulated in a cell-cycle dependent manner.
Phosphorylation of hTERT in mitosis
To investigate hTERT regulation in mitosis, we first treated HeLa cells with nocodazole. We confirmed that cells accumulated in mitotic phase by assessing phospho-histone H3 (Ser10) levels ( Fig. 1B, lower panel) . When we examined the migration of endogenous hTERT in the mitotic phase by SDS-PAGE, we found that endogenous hTERT isolated by immunoprecipitation with anti-hTERT mAb (clone 10E9-2) (16) migrated slower than ectopically expressed FLAG-tagged hTERT ( Fig. 1B, upper panel) . We thus speculated that endogenous hTERT in mitotic phase is posttranslationally modified. We treated hTERT immunoprecipitated with anti-hTERT mAb (clone 10E9-2) from mitotic cells with l phosphatase and found that phosphatase treatment diminished the mobility shift of hTERT protein (Fig. 1C) . This observation suggested that hTERT is phosphorylated in mitosis.
To identify the mitotic phosphorylation sites in hTERT, we ectopically expressed hTERT in HEK-293T (293T) or HeLa cells followed by treatment with nocodazole to arrest cells in mitosis.
We isolated hTERT by immunoprecipitation and performed mass spectrometry (MS) analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS). We used the Mascot software package (version 2.5.1; Matrix Science) to search for the mass of each peptide ion peak against the SWISS-PROT database (Homo sapiens, 20,205 sequences in the Swiss prot_2015_09.fasta file) and to identify the phosphorylation sites. We identified four phosphopeptides in 293T cells and one phosphopeptide in HeLa cells. The phosphopeptide 241 GAAPEPERpTPVGQGSWAHPGR 261 was found in both 293T and HeLa cells ( Fig. 1D) . Moreover, phosphorylation sites analysis by the Mascot software revealed that only the residue at threonine 249 (T249) was phosphorylated in the phosphopeptide (amino acids 241-261) (Supplementary Data S1). We found that T249 is conserved in primates, while serine 227, corresponding to nuclear localization of hTERT by the Aktmediated phosphorylation (17) , is conserved among most mammals (Fig. 1E) .
To interrogate the consequences of hTERT phosphorylation at T249, we generated rabbit polyclonal antibodies that specifically recognize phosphothreonine 249 (anti-249T-P). We confirmed that treatment of hTERT isolated from mitotic HeLa cells with l phosphatase or suppression of hTERT by hTERT-specific siRNAs ablated the signal detected by this antibody (Figs.
1F and 1G). Taken together, these observations indicate that hTERT at T249 is phosphorylated in mitosis.
We noted that the sequence surrounding T249 is part of a motif that is frequently phosphorylated in mitosis and has been implicated as a target of the serine-threonine kinase cyclindependent kinase 1 (CDK1) (18) . To investigate whether CDK1 phosphorylates hTERT, we performed in vitro kinase assay using recombinant hTERT fragment proteins (amino acids 191-306) and CDK1-cyclinB proteins followed by MS analysis. We used phosphate-affinity gel electrophoresis (Phos-tag SDS-PAGE) to detect the phosphorylation status of hTERT fragment incubated with purified CDK1-cyclinB or IKK2_2-664 used as a control of serine-threonine kinase.
Phos-Tag SDS-PAGE allows the migration delay of phosphorylated proteins relative to their unphosphorylated counterparts in gels containing a phosphate-binding tag (19) . The Phos-tag SDS-PAGE revealed that hTERT_191-306 proteins were phosphorylated by CDK1-cyclinB and IKK2_2-664 in vitro ( Fig. 1H, upper panel) . The hTERT_191-306 protein phosphorylated by CDK1-cyclinB was detected with the anti-249T-P antibodies, but we were unable to detect the protein phosphorylated by IKK2_2-664 with the anti-249T-P antibodies (Fig. 1H , lanes 6 and 7 on lower panel), suggesting that IKK2 does not phosphorylate hTERT at T249 in vitro. To further confirm that hTERT T249 is phosphorylated by CDK1-cyclinB in vitro, we performed MS analysis using LC-MS/MS and identified that threonine 249 was phosphorylated by CDK1-cyclinB, not by IKK2_2-664 ( Fig. S3 and Table S1 ). These observations confirmed that CDK1-cyclinB phosphorylates hTERT T249.
To further study hTERT phosphorylation at T249, we generated a mouse monoclonal antibody that specifically recognize phosphothreonine 249 (TpMab-1). We confirmed that the antibody specifically detected phosphorylation signals of hTERT T249 phosphorylated by CDK1-cyclinB in vitro similar to anti-249T-P polyclonal antibodies ( Fig. 1I ).
Phosphorylation of hTERT at T249 occurs in cancers from clinical samples
To assess whether T249 was phosphorylated in human cancers, we first validated the specificity of the anti-249T-P pAbs for immunohistochemical (IHC) staining in human tissue sections. The observed signals were fully abolished by the absorption treatment with phosphopeptide ( Fig. S4) ,
whereas treatment with nonphosphopeptide did not alter the signals (Fig. S4) , indicating that the antibodies are specific and applicable for immunohistochemical analyses.
To investigate the relationship between a progression of pancreatic cancer and hTERT phosphorylation, we stained each pancreatic precancerous lesions with anti-249T-P antibodies. We found no evidence for anti-249T-P staining in normal ducts, PanIN-1 and -2 but observed robust staining in PanIN-3 ( Figs. 2A-2E) . In pancreatic adenocarcinomas, we found staining of hTERT phosphorylation with anti-249T-P pAbs in the nucleus (Fig. 2F) . Both normal and atypical multipolar mitotic images exhibited strong hTERT phosphorylation ( Fig. 2G) . Furthermore, some cases displayed strong signals of hTERT phosphorylation in poorly differentiated areas ( Fig. 2H, upper lesion) and cancer cells that exhibited squamous differentiation ( Fig. 2I) . We examined the number of cells stained with anti-249T-P antibodies, referred as 249T-P positive cells, in each pancreatic ductal lesion (Fig. 2J) . The number of 249T-P positive cells was the highest in carcinomas, followed by PanIN-3, PanIN-2, PanIN-1, and duct epithelium (p<0.05). To consolidate the specificity of the data for IHC with anti-249T-P pAbs, we stained the pancreatic cancer samples with TpMab-1 monoclonal antibody, that also specifically recognize phosphothreonine 249 ( Fig.   1I ), in serial sections prepared from the identical pancreatic cancer lesions ( Figs. S5A-S5F) . We observed the identical staining pattern with these antibodies in the nucleus of the same cells and confirmed that phosphorylation signals of hTERT T249 were detected in pancreatic carcinoma.
Finally, we found that 249T-P positive cases showed higher incidence of lymph node metastasis than 249T-P negative cases (Table S2 ).
In addition, we conducted IHC with anti-249T-P pAbs on hepatocellular carcinoma (HCC) samples. We failed to detect the specific signals in non-cancerous lesions ( Fig. 2K ) but found strong nuclear staining in HCC lesions obtained from the same patient ( Fig. 2L) . Moreover, we found strong hTERT phosphorylation at the T249 in poorly differentiated cases ( Fig. 2M and Table S3 ) and in more advanced cancers ( Fig. 2N ), suggesting that hTERT phosphorylation at T249 is associated with HCC grade (Table S3 ). In consonance with this observation, we found that patients whose tumors lacked anti-249T-P staining had longer overall survival (OS; p=0.048) and recurrence-free survival (RFS; p=0.0261) than patients whose cancers showed with anti-249T-P staining (Figs. 2O and 2P). These observations suggest that hTERT phosphorylation at T249 occurs in cancers, more frequently in advanced cancers.
Consequences of hTERT phosphorylation
To study the consequence of hTERT phosphorylation, we used l phosphatase to remove all phosphate groups from hTERT immunoprecipitated with the anti-hTERT mAb (clone 10E9-2) and then performed a quantitative direct telomerase assay (15, 20) and an RNA dependent RNA polymerase (RdRP) assay (Fig. 3A) . We found that phosphatase treatment of hTERT reduced hTERT-dependent RdRP activity but had no measurable effect on telomerase activity.
To confirm that CDK1 phosphorylates hTERT at T249, we suppressed CDK1 with CDK1specific siRNAs (Fig. 3B) . Suppression of CDK1 decreased cell proliferation by 70%, and we observed that introduction of CDK1-specific siRNAs #1, 2, and 3 suppressed hTERT T249 phosphorylation by 98%. Together, these observations strongly suggest that CDK1 is required for the phosphorylation of hTERT at T249.
Moreover, we found that the RdRP activity of hTERT was substantially diminished by CDK1 knockdown while suppression of CDK1 had no effect on telomerase activity ( Fig. 3C) , indicating that phosphorylation by CDK1 is required for the RdRP activity of hTERT. These results suggest that hTERT proteins are phosphorylated by CDK1 in mitosis and the phosphorylation is not required for the telomerase activity but for the RdRP activity of hTERT.
To further confirm that CDK1 specifically phosphorylates hTERT T249, we treated HeLa cells with CDK1 inhibitor, RO-3306 (21) . Inhibition of CDK1 activity diminished the phosphorylation of hTERT T249 ( Fig. 3D ) and reduced the RdRP activity of hTERT ( Fig. 3E) .
Thus, both suppressing CDK1 expression or inhibiting CDK1 kinase activity decreased the phosphorylation of hTERT at T249 and hTERT-mediated RdRP activity.
Consequences of phosphorylation of hTERT on T249
To further assess the consequences of phosphorylation of hTERT T249 in the human cell lines, we created hTERT mutants where we substituted the threonine 249 of hTERT with alanine (T249A) or glutamic acid (T249E). We introduced these mutants in telomerase-negative human fibroblast BJ cells and analyzed the telomerase activity of the mutant proteins by the telomeric repeat amplification protocol (TRAP) assay. We found that both of these mutant hTERT alleles exhibited telomerase activity equivalent to that observed for wild type hTERT (WT-hTERT) ( Fig. 4A , left panel). We confirmed the TRAP assay findings by introducing these hTERT mutants in 293T cells and measured the telomerase activity by a quantitative assay as measured by the direct telomerase assay (15, 20) (Fig. 4B) . We verified that these mutants retained telomerase activity comparable to WT-hTERT and did not interfere with endogenous hTERT. Consistent with a previous report (12) , ectopic expression of WT-hTERT protein slightly increased measured telomerase activity. We also assessed whether these two mutants elongated telomeres when expressed in cells by performing Southern blotting for telomere restriction fragments. We analyzed the telomere length in the BJ cells at 8 population doubling (PD) after infection of the two mutants and found that T249A and T249E mutants elongated telomeres ( Fig. 4A, right panel) . These data demonstrated that telomerase activity of the mutants was intact.
We next examined whether introduction of hTERT mutants in 293T cells altered hTERTdependent RdRP activity (22) . We found that expression of the phosphorylation-defective mutant hTERT T249A decreased RdRP activity ( Fig. 4C) , while ectopic expression of hTERT T249E increased RdRP activity, suggesting that this mutant acts as a phosphomimetic mutant. These observations confirmed that the phosphorylation of hTERT T249 is required for the RdRP activity but not for reverse transcriptase activity of hTERT.
To further assess the biological effects of phosphorylation of hTERT T249 in cancer cell lines, we expressed hTERT T249A, hTERT T249E, or a control vector expressing only a drug resistance marker into several well-characterized cancer cell lines; two telomerase/RdRP-positive ovarian cancer cell lines (14) , PEO1 and PEO14, and a telomerase/RdRP-positive patient-derived hepatocellular carcinoma (HCC) MT cells ( Fig. 4D) . In PEO1, PEO14 and MT cells, the expression of hTERT T249A dramatically decreased the cell proliferation (0.73-, 0.18-and 0.50-fold, respectively) while the hTERT T249E showed a minor effect on cell proliferation (1.03-, 1.01-and 1.19-fold, respectively) ( Fig. 4E) . These observations suggest that phosphorylation-defective hTERT T249A interferes with hTERT-mediated RdRP activity and the inhibition of RdRP activity causes inhibitory effects on the cell growth. In contrast, hTERT T249E failed to alter the proliferation of these cell lines.
To further evaluate the influence of hTERT phosphorylation at T249 using patient derived xenograft (PDX) models in vivo, we introduced hTERT T249A (MT+T249A) or a control retroviral vector (MT-Control) into MT (patient-derived HCC) cells and implanted these cells subcutaneously into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Six of eight mice harboring MT+T249A failed to form tumors ( Fig. 4F , left panel) and the volume of tumors from mice harboring MT+T249A was significantly smaller than those from mice with MT-Control ( Fig.   4F , right panel; p=0.0028). Taken together, these observations indicate that phosphorylation of hTERT at T249 is required for cancer cell proliferation through activation of RdRP activity of hTERT.
CRISPR-Cas9 genome editing to introduce alanine or glutamic acid substitutions at T249
Although the expression of these hTERT alleles clearly separated hTERT mediated telomerase and RdRP activity, endogenous hTERT is expressed at low levels even in cancer cells. To assess whether the phosphorylation of T249 affected endogenous hTERT function, we used CRISPR-Cas9 genome editing to introduce alanine or glutamic acid substitutions at T249 in the endogenous hTERT locus in 293T cells ( Fig. 5A) . After introduction of Cas9 and guide RNAs with donor DNAs into 293T cells, we selected clones and confirmed that the mutations were introduced by PCR amplification, restriction enzyme digestion, and Sanger sequencing (Figs. 5B and 5C). Control cells, Control-CRISPR, were selected from clonal selection of cells expressing Cas9 and no guide RNAs. We confirmed that T249A-CRISPR and T249E-CRISPR were expressed at a level similar to that of endogenous hTERT in the Control-CRISPR cells ( Fig. 5D , lower panel).
Using these genome-edited 293T cells, we confirmed that substitution of T249 to alanine ablated hTERT-dependent RdRP activity ( Fig. 5D , upper panel). Similar to ectopic expression of the mutant proteins ( Fig. 4C) , hTERT with T249E mutation increased the RdRP activity while hTERT with T249A mutation decreased the activity. These results confirmed that phosphorylation of T249 is essential for RdRP activity of hTERT.
To evaluate the direct influence of hTERT phosphorylation at T249 using xenograft models in vivo, we inoculated Control-CRISPR or T249A-CRISPR subcutaneously into NOD/SCID mice.
Four of eight mice harboring T249A-CRISPR failed to form tumors ( Fig. 5E , upper panel) and the volume of tumors from mice with T249A-CRISPR was significantly smaller than those from mice with Control-CRISPR ( Fig. 5E , lower panel; p=0.0469). We confirmed that RdRP-deficient hTERT proteins isolated from T249A-CRISPR retained telomerase activity comparable to the hTERT from Control-CRISPR ( Fig. 5F) . Taken together, these observations confirmed that phosphothreonine 249 in hTERT is essential for cancer cell proliferation through activation of RdRP activity of hTERT.
Effects of hTERT phosphorylation on gene expression
In prior work, we showed that hTERT-mediated RdRP activity affects gene expression by affecting RNA levels (16) . To identify genes whose expression is altered when hTERT cannot be phosphorylated, we examined gene expression at promoter level using Cap Analysis of Gene Expression (CAGE) method (23) for Control-CRISPR and T249A-CRISPR in triplicate. We found 3,482 CAGE peaks, indicating each transcriptional start site (TSS) and the expression level as a promoter activity, that exhibited altered the activity in these cells (FDR<1e-4), where 1,926 and 1,556 were up-and down-regulated in T249A-CRISPR. In particular, we found that three independent CAGE peaks of the transcription factor, forkhead box O4 (FOXO4), were upregulated in T249A-CRISPR while the most upstream TSS, p1, showed no change ( Fig. 6A) . We confirmed the increase in expression of FOXO4 proteins in T249A-CRISPR by immunoblotting ( Fig. 6B) . To further confirm that the phosphorylation of hTERT T249 by CDK1 specifically affects the expression of FOXO4, we treated HeLa cells with CDK1 inhibitor, RO-3306. Inhibition of CDK1 activity increased the expression of FOXO4 mRNA in a dose-dependent manner (Fig. S6) .
Gene ontology (GO) term analysis showed enrichment of genes associated with "cell cycle phase transition" (GO:0044770, Table S4 ) within the upregulated genes in the T249A-CRISPR.
Notably, FOXO4 is annotated in this GO term and functions as tumor suppressor proteins in various cancers by preventing proper cell cycle regulation (24) (25) (26) (27) (28) (29) . These findings indicate that phosphorylation of T249 on hTERT regulates the expression of FOXO4 negatively in cancer cell lines and increase of FOXO4 expression in T249A-CRISPR is correlated with a decrease of tumor formation.
To determine whether FOXO4 is a direct target of hTERT phosphorylated at T249, we performed IP-RT-PCR experiments with RNAs isolated from hTERT-IP samples of Control-CRISPR and T249A-CRISPR. We isolated hTERT-RNA complexes by immunoprecipitation with an anti-hTERT mAb (clone 10E9-2) from Control-CRISPR and T249A-CRISPR cells, and purified RNAs from the immune complexes with DNase treatment. cDNAs were synthesized with strandspecific primers, and we performed PCR using primers to amplify the first exon of FOXO4 mRNAs.
We confirmed that endogenous hTERT immunoprecipitated from Control-CRISPR interacts with the first exon of FOXO4 mRNAs and that there was a 50% reduction of hTERT associated with FOXO4 mRNAs isolated from T249A-CRISPR cells ( Fig. 6C) . We also found that hTERT from Control-CRISPR interacts with antisense RNAs (asRNAs) of FOXO4 mRNA under condition in which we failed to recover RNase P RNA (22) . CRISPR+shFOXO4 exhibited a higher tumor growth rate and the volume of tumors from mice with T249A-CRISPR+shFOXO4-1 and -2 was significantly larger than those from mice with T249A-CRISPR+shGFP ( Fig. 6G, lower panel; p=0.0008 and p=0.0136, respectively). These observations verified that perturbation of FOXO4 expression by specific shRNAs rescued the defects in tumor formation ability in T249A-CRISPR.
Discussion
Telomerase plays an essential role in maintaining telomeres. The expression of the catalytic subunit of telomerase hTERT is upregulated in the majority of human cancers, most often due to mutations in its promoter. Here we demonstrate that hTERT is phosphorylated by CDK1 in mitosis and that this phosphorylation event affects a second hTERT function, RNA dependent RNA polymerase activity without affecting hTERT function at telomeres. This mitotic function of hTERT correlates with tumor aggressiveness and is necessary for tumor formation. Together these observations separate the telomere and non-telomere directed functions of hTERT and identify a novel mechanism that regulates hTERT RdRP activity.
It is well accepted that telomerase recruitment to telomeres occurs in S-phase in many organisms (10, 30) . While these observations indicate that telomerase recruitment to telomeres and telomerase activation are regulated in a cell cycle dependent manner, there have been two reports that studied telomerase activity outside the S-phase (31, 32) . Specifically, these reports showed that Xenopus telomerase activity was active in mitotic phase and modulated chromatin configuration. In consonance with these findings, we previously reported that hTERT localizes to both mitotic spindles and centromeres, that hTERT protein expression level is enriched in mitosis, and that hTERT-RdRP activity is present in nuclear extracts derived from several cancer cell lines arrested in mitosis (14, 16, 33) . Here we have confirmed and extended these findings by identifying the mitotic kinase CDK1 as a key regulator of hTERT RdRP but not telomerase activity.
Several laboratories have shown that hTERT is phosphorylated (17, (34) (35) (36) . Specifically, four phosphorylation sites have been reported, serine 227 (17), serine 457 (36) , tyrosine 707 (35) and serine 824 (34) . Serine 227 is located in a canonical nuclear localization signal, is phosphorylated by Akt1, and promotes nuclear localization of hTERT (17) . Serine 824 is also phosphorylated by Akt1 and is necessary for hTERT-mediated telomerase activity (34) . Serine 457 is phosphorylated by DYRK2 during G2/M and promotes ubiquitination of hTERT proteins (36) .
Tyrosine 707 is phosphorylated by C-Src under oxidative stress to alter subcellular localization of hTERT (35) . We were unable to detect these sites by MS analysis in this study with mitotic cells.
These phosphorylation sites were identified from consensus sequences for specific kinases, and MS analysis was not conducted in previous reports. We speculate that the amount and level of phosphorylation in these sites may be difficult to detect using MS analysis. In addition, previous reports demonstrated that phosphorylation affect either telomerase activity or subcellular localization of hTERT whereas this study identifies the novel phosphorylated site that does not affect telomerase activity.
Threonine 249 in hTERT is conserved in human and primates but not in the other mammals and yeast ( Fig. 1E ), suggesting that phosphorylation-dependent RdRP activity of TERT is restricted to primates. When we introduced substitutions of T249 (T249A and T249E) into endogenous hTERT, we found that these mutants did not affect telomerase activity at telomeres but instead affected RdRP activity and inhibited the tumorigenic potential of human cancer cell lines.
These observations suggest that phosphorylation of hTERT at T249 contributes to tumor formation independent of its reverse transcriptase activity to elongate telomeres. Furthermore, we found that phosphorylation of hTERT at T249 regulates the expression of the tumor suppressor gene, FOXO4, in cancer cell lines ( Fig. S7) . Expression levels of FOXO4 inversely correlate with tumor formation and incidence of clinical metastasis (24) (25) (26) (27) (28) (29) In addition, we have identified CDK1 as a kinase that phosphorylates hTERT at T249 in mitosis. CDK1 is essential for cell division in the embryo and deficiency in CDK1 in mouse model results in embryonic lethality in the first cell divisions (37) . Moreover, CDK1 is sufficient to drive the cell cycle in all cell types (37) . Previous reports demonstrated that CDK1 expression is upregulated in many human malignant tumor tissues and that CDK1 activity correlates with the prognosis of patients with tumors (38) (39) (40) (41) (42) (43) . In addition, loss of CDK1 in the liver in CDK1 conditional knockout mice showed complete resistance against tumorigenesis (44) indicating that CDK1 is required for tumorigenesis in liver cancer. Here we report a link between CDK1 and phosphorylation of hTERT at T249, and the phosphorylation occurs more frequently in aggressive and advanced cancers in clinical samples, suggesting an additional role for CDK1 in cancer progression. These observations implicate CDK1 and phosphorylation of hTERT T249 as an approach to inhibit a key cancer-associated function of hTERT.
Materials and Methods
Antibodies
Anti-hTERT mouse monoclonal antibodies (mAbs, clones 10E9-2 and 2E4-2) were generated and described the specificity as reported previously (16) . Anti-hTERT mouse mAb (clone 2E4-2), anti-hTERT rabbit mAb (Abcam, ab32020), anti-phospho-histone H3 (Ser10) rabbit polyclonal antibodies (pAbs) (Merck, 06-570), anti-cdc2 (POH1) mouse mAb (Cell Signaling Technology, 9116), anti-b-actin (AC-15) mouse mAb (Sigma-Aldrich, A5441), anti-FOXO4 rabbit mAb (Abcam, ab128908) and anti-GAPDH mouse mAb (MBL Co., Ltd., M171-3) were used for immunoblotting (IB). Anti-hTERT mAb (clone 10E9-2: MBL Co., Ltd., M216-3) and anti-hTERT sheep pAbs (Abbexa Ltd., abx120550) were used for immunoprecipitation (IP).
Generation of phospho-specific polyclonal antibodies
To generate phosphospecific antibodies against phosphorylated threonine 249 of hTERT (anti-249T-P), hTERT phosphopeptide 244 CEPERpTPVGQG 254 was used to immunize rabbits. The antibodies were purified from the antisera by using hTERT phosphopeptide-conjugated Resin and then further purified by passing it through hTERT nonphosphopeptide-conjugated Resin. with Imject Alum (Thermo Fisher Scientific). After two additional immunizations of 100 µg, a booster injection of 100 µg was given i.p. 2 days before spleen cells were harvested. The spleen cells were fused with P3U1 cells (ATCC) using PEG1500 (Roche Diagnostics,). The hybridomas were grown in RPMI 1640 medium (Nacalai Tesque) at 37°C in a humidified atmosphere containing 5% CO2 and 95% air, supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific), hypoxanthine, aminopterin, and thymidine (HAT) selection medium supplement (Thermo Fisher Scientific), and 5% BriClone Hybridoma Cloning Medium (QED Bioscience). One hundred units/ml penicillin, 100 µg/ml streptomycin, and 25 µg/ml amphotericin B (Nacalai Tesque) were added to the culture medium. Plasmocin (5 µg/ml; InvivoGen) was also used to prevent Mycoplasma contamination. The culture supernatants were screened using enzyme-linked immunosorbent assay (ELISA) for binding to hTERT phosphopeptide and nonphosphopeptide.
Generation of hybridoma producing phospho-specific monoclonal antibody
Enzyme-Linked Immunosorbent Assay (ELISA)
Peptides were immobilized on Nunc Maxisorp 96-well immunoplates (Thermo Fisher Scientific) at 1 µg/ml. After blocking with SuperBlock T20 (PBS) Blocking Buffer (Thermo Fisher Scientific), the plates were incubated with culture supernatant with subsequent 1:2000 diluted peroxidaseconjugated anti-mouse IgG (Agilent Technologies). The enzymatic reaction was conducted with 1-
Step Ultra TMB-ELISA (Thermo Fisher Scientific). The optical density was measured at 655 nm using an iMark microplate reader (Bio-Rad Laboratories). These reactions were performed with a volume of 50-100 µl at 37°C. Mitotic cell synchronization was performed as described previously (16) . Briefly, cells were switched to medium containing 2.5 mM thymidine (Nacalai Tesque) and incubated for 24 hours.
Cell culture and mitotic cell synchronization
Six hours after release, cells were incubated in medium containing 0.1 µg/ml nocodazole (Sigma-Aldrich) for 16 hours. After shake-off, mitotic cells were retrieved. Cells arrested in mitosis with nocodazole were confirmed by IB using anti-phospho-histone H3 (Ser10) antibodies.
Transfection of siRNAs
For suppression of hTERT or CDK1 expression, HeLa cells were transfected with siRNAs using Lipofectamine 2000 (Thermo Fisher Scientific). After 48 h of incubation, cells were treated with 0.1 µg/ml nocodazole for 16 hours. The sequences of siRNAs against hTERT (13) are listed in Table   S5 . MISSION siRNAs Hs_CDC2_4049_s and Hs_CDC2_4049_as, Hs_CDC2_4053_s and Hs_CDC2_4053_as, Hs_CDC2_6210_s and Hs_CDC2_6210_as, and Hs_CDC2_4050_s and Hs_CDC2_4050_as were used for CDK1 siRNA #1, CDK1 siRNA #2, CDK1 siRNA #3 and CDK1 siRNA #4, respectively. MISSION siRNA Universal Negative Control #1 (Sigma-Aldrich) was used as a negative control.
IP-IB of hTERT
The IP-IB assay was performed as described previously (16) . In brief, 1× 10 7 cells were lysed in 1 ml of Lysis buffer A (0.5% NP-40, 20 mM Tris-HCl (pH 7.4), and 150 mM NaCl). After sonication, lysates were cleared of insoluble material by centrifugation at 21,000 × g at 4°C for 15 min. One milliliter of lysate was pre-absorbed with 40 µl of Pierce Protein A Plus Agarose (Thermo Fisher Scientific) for 30 min at 4°C. Pre-absorbed lysate was mixed with 10 µg of anti-hTERT mAb (clone 10E9-2) or 30 µg of anti-hTERT pAbs (abx120550) and 40 µl of Pierce Protein A Plus Agarose, and incubated overnight at 4°C. Immune complexes were washed three times with Lysis buffer A and eluted in 2× SDS loading buffer (2% b-mercaptoethanol, 20% glycerol, 4% SDS, and 100 mM Tris-HCl (pH 6.8)), and then subjected to SDS-PAGE in 8% polyacrylamide gels. Anti-hTERT mouse mAb (clone 2E4-2) and Mouse TrueBlot ULTRA Anti-Mouse Ig HRP (Rockland) or anti-hTERT rabbit mAb (ab32020) and anti-rabbit IgG HRP (GE Healthcare) were used for IB to detect whole hTERT proteins. Anti-phospho hTERT rabbit pAbs (anti-249T-P) and anti-rabbit IgG HRP (GE Healthcare) or anti-phospho hTERT mouse mAb (TpMab-1) and anti-mouse IgG HRP (GE Healthcare) were used for IB to detect phosphorylated hTERT proteins.
For the l phosphatase treatment, the beads suspension with immune complexes was treated with 2,000 U of l protein phosphatase (Bio Academia) and 2 mM MnCl2 in l-PPase reaction buffer (50 mM Tris-HCl (pH 7.6), 100 mM NaCl, 2 mM DTT, 100 µM EDTA and 0.01% Brij 35) and incubated at 30°C for 30 min.
Identification of phosphopeptides by mass spectrometric protein profiling
The protein samples immunoprecipitated with anti-hTERT mAb (clone 10E9-2) were separated by 12.5% SDS-PAGE and subjected to in-gel digestion using trypsin (45) . The tryptic digests were subjected to liquid chromatography coupled with nanoelectrospray tandem mass spectrometry (Finnigan LTQ Orbitrap XL mass spectrometer; Thermo Fisher Scientific). The Mascot software package (version 2.5.1; Matrix Science) was used to search for the mass of each peptide ion peak against the SWISS-PROT database (Homo sapiens, 20,205 sequences in the Swiss prot_2015_09.fasta file) using the following parameters: 1 missed cleavage; fixed modification: carboxymethylation (C); variable modification: oxidation (M), phosphorylation (ST), phosphorylation (Y); search mode: MS/MS ion search with decoy database search included; peptide mass tolerance ± 10 ppm; MS/MS mass tolerance ± 0.8 Da; peptide charge: 2+ and 3+. All peptide information of TERT proteins detected in this study is shown in Supplementary Data S1. For baculovirus-insect cell expression of active form of human IKK2 (IKK2_2-664), we used the Bac-to-Bac Baculovirus Expression System (Thermo Fisher Scientific). The target cDNA fragment, corresponding to 2-664 residues of human IKK2, was sub-cloned into the pDEST vector (Thermo Fisher Scientific). Polyhistidine affinity-tagged IKK2_2-664 was expressed in insect Sf9 cells at a multiplicity of infection (MOI) of 1.0 with a recombinant baculovirus that expresses IKK2_2-664. The cells from each culture were harvested 48 hours post-infection, and the cell pellets were washed once with PBS and were immediately frozen in liquid N2. The recombinant IKK2_2-664 protein was purified as described previously (47) . Table S1 .
In vitro kinase assay
IP-RdRP assay
The IP-RdRP assay was performed as described previously (16) . TERT protein was immunoprecipitated from human cell lines as described for the IP-IB assay with anti-hTERT mAb 
Generation of phosphorylation-inhibitory or phosphomimetic mutant plasmids
For site-directed mutagenesis, QuikChange II XL site-directed mutagenesis Kit (Agilent Technologies) was used. In brief, site-directed mutagenesis PCRs were performed using PfuUltra High Fidelity DNA polymerase following the manufacturer's protocol with either the pBABE-puro-hTERT retroviral vector or the pNK-FLAG-Z-hTERT expression vector as template plasmids.
Sequences of mutagenic primers are listed in Table S5 . PCR products were digested with DpnI restriction enzyme for 1 hour at 37°C and then transformed into XL-10-Gold ultracompetent cells.
Mutations were confirmed by Sanger sequencing.
Telomere analysis
For the telomeric repeat amplification protocol (TRAP) assay, 1× 10 5 cells were suspended in 200 µl of TRAP lysis buffer (10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM EGTA, 0.5% CHAPS, 10% glycerol, 100 µM Pefabloc SC, and 0.035% 2-mercaptoethanol). The TRAP assay was performed with 5 µl of the suspension as described previously (13) .
To measure telomere length by Southern blotting, genomic DNAs were isolated, digested with HinfI and AfaI, electrophoresed in a 0.8% agarose gel and hybridized with a 32 P-labeled telomeric (CCCTAA)3 probe as described previously (49) .
Direct telomerase assay
For the direct telomerase assay, we modified the original methods (15, 20) . Briefly, TERT protein was immunoprecipitated from human cell lines as described for the IP-IB assay without sonication.
Immune complexes were washed three times with Lysis buffer A, and then suspended in 30 
Generation of stable cell lines and proliferation assay
Amphotropic retroviruses were created as described (50) We used the following short hairpin RNA (shRNA) vectors, shFOXO4-1 (TRCN0000010291) and shFOXO4-2 (TRCN0000039720), constructed by The RNAi Consortium and the sequences are listed in Table S5 . shGFP was used as the control. These vectors were used to make amphotropic lentiviruses, and the cell populations were selected with puromycin (2 µg/ml) for 3 days. To generate proliferation curves, cells were plated in triplicate and counted in a Z2 Particle Count and Size Analyzer (Beckman-Coulter).
RT-PCR and quantitative RT-PCR (qPCR)
Total cellular RNA was isolated using TRIzol (Thermo Fisher Scientific), treated with RQ1 DNase Table S5 .
Genome editing using CRISPR-Cas9
The PuroCas9 plasmid which consists of three cassettes for Cas9 cDNA, chimeric guide RNA and puromycin cDNA was generated by modifying the px330 plasmid (addgene #42230) (51). Cas9 and puromycin resistance genes are expressed under the control of the CAG promoter (52) Table S5 .
Xenotransplantation
Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice (Charles River Laboratories, Inc.) were used as recipients for xenotransplantation. 1x 10 5 cells of MT cells introduced retroviral vectors or 293T-CRISPR cells were suspended in a mixture of serum-free medium and Matrigel (BD Biosciences; 1:1 volume). The mixture was injected subcutaneously through a 26-gauge needle into the right dorsal areas of anesthetized NOD/SCID mice. We monitored tumor formation and tumor size every two or three days, and dissected out the tumors within a month after engraftment.
CAGE sequencing and data analysis
Of each of the total RNAs extracted from two triplicates (Control-CRISPR and T249A-CRISPR), 3
µg was used to prepare a sequencing library according to the non-Amplified non-Tagging Illumina Cap Analysis of Gene Expression (nAnT-iCAGE) (23) by using CAGE library preparation kit (DNAFORM), and sequenced by NextSeq500 platform (Illumina). After discarding sequences with ambiguous (N) and low-quality (Phred<30), the remaining reads were aligned with the human reference genome (GRCh37) by STAR v2.6.0a (54) with a guide of known junctions of RefSeq transcripts (55) . The alignments with mapping quality more than 20 were selected, and their 5'ends were counted based on the robust set of CAGE peaks identified in a previous study (56) and provided at the FANTOM5 web resource (57) . The read counts were normalized as counts per million (CPM) with relative log expression (RLE) method (58) . The sequencing results were visualized using Integrative Genomics Viewer (IGV) (59) . This normalization and subsequent differential analysis were conducted with edgeR (60), where FDR<1e-4 were used as a criteria for statistical significance. p value of GO term enrichment was assessed with DAVID v6.8 (61) using all human genes as a background set, and only the terms that have less than 100 corresponding genes were chosen to exclude very general GO terms such as "biological process". The obtained CAGE reads are available in the DDBJ Sequence Read Archive (DRA) with accession number (DRA007587).
Clinical pancreatic tissue samples
The pancreatic tissues used in this study were obtained from patients who underwent surgical Tissues were fixed in 10% buffered formalin and then subjected to standard tissue processing and paraffin embedding. The tissues were sliced serially into sections 3 µm thick for hematoxylin and eosin (H&E) and immunohistochemical staining. Pathological specimens were diagnosed by our pathologists based on the World Health Organization Classification of Tumours of the Digestive System (62) . PanIN lesions were classified as PanIN-1, -2 or -3.
Immunohistochemistry (IHC) of pancreatic tissue samples
Paraffin-embedded sections (3 µm) were subjected to immunostaining. After deparaffinization, the tissue sections were preheated in HEAT PROCESSOR Solution pH 6 (Nichirei) for 20 min at 100°C.
Then, sections were incubated for 5 min at room temperature with Protein Block Serum-Free (Dako).
The tissue sections were then incubated with the anti-249T-P pAbs or TpMab-1 mAb (1: 250 in dilution) for 1 hour at room temperature. Endogenous peroxidase activity was blocked by 3% H2O2 for 5 min at room temperature. Sections were incubated with Second antibody (REAL EnVision, Dako). Bound antibodies were detected using diaminobenzidine tetrahydrochloride as the substrate.
The sections were then counterstained with Mayer's hematoxylin. Negative control tissue sections were prepared by omitting the primary antibody. As for the evaluation of immunostaining, proportion of positively stained nucleus of cancer cells were analyzed at magnification x200. For statistical analysis, we divided patients into 2 groups; 249T-P positive and negative groups at 10% cutoff value.
Statistical analysis of pancreatic tissue sample
The level of significance was set at p<0.05 for all analyses. Statistical analyses were performed using the StatView J version 5.0 software package (SAS Institute).
Clinical HCC samples
A total of 100 HCC patients who received surgery at Kanazawa University Hospital from 2008 to 2013 were enrolled in the study. This study was approved by the Institutional Review Board at Kanazawa University (IRB # 1065) and all patients provided written informed consent.
IHC of HCC samples
IHC of HCC samples was performed using DAKO Envision+ kits (Agilent Technologies) according
to the manufacturer's instruction. Briefly, formalin-fixed paraffin-embedded tissue slides were deparaffinized, rehydrated, and immediately proceeded for antigen retrieval (120°C for 5 min) using autoclaves and target retrieval solution, citrate pH 6 (Agilent Technologies). Slides were immersed with blocking solution (Agilent Technologies) for 15 min and subsequently replaced with anti-249T-P pAbs diluted at 1:250 with antibody diluent solution (Agilent Technologies). Slides were incubated at 4°C overnight and then washed and visualized with DAB+ substrate chromogen (Agilent Technologies). The patient groups with 249T-P positive and negative were divided at 10% cutoff value.
Statistical analysis of HCC samples
Kaplan-Meier survival analysis was performed in GraphPad Prism software 6.0 (GraphPad Software Table S1 . MS data of hTERT from in vitro kinase assay. Table S2 . Clinicopathological analysis of the hTERT T249 phosphorylation in pancreatic cancer. Table S3 . Clinicopathological analysis of the hTERT T249 phosphorylation in liver cancer. Table S4 . GO analysis of genes differentially expressed in T249A-CRISPR cells (FDR < 0.01). Table S5 . Sequences of primers, siRNAs and oligos used in the work.
Supplementary Data S1. MS data of hTERT isolated from 293T or HeLa cells synchronized to mitotic phase.
